20 articles
60-patient trial explores whether metformin, combined with standard therapy, could slow Parkinson's progression through metabolic pathways.
A Phase 3 trial investigates whether the GLP-1 drug liraglutide can slow cognitive decline in T2DM patients at elevated Alzheimer's risk.
Online portal reveals public preferences for dementia treatments, with safety concerns outweighing efficacy in drug selection decisions.
A Danish double-blind RCT tests a novel at-home electromagnetic field headband against sham for moderate-to-severe depression over 8 weeks.
A new study warns that diabetes medications could confound Alzheimer's biomarker studies, distorting our understanding of the diabetes-dementia link.
Cassava Sciences' 76-week Phase 3 trial of simufilam for Alzheimer's was terminated, raising questions about the drug's future.
Phase 1b trial tests escalating doses of experimental Alzheimer's treatment BMS-984923 for safety and tolerability in older adults.
A pilot RCT tested whether a smartphone app could improve quality of life and treatment adherence in HIV-positive patients aged 60+.
Stanford researchers find pioglitazone and liraglutide improve CNS insulin signaling, measured via neuron-derived vesicles in blood.
A study of 100,000 people found semaglutide users had 44% lower depression risk and 42% fewer psychiatric hospitalizations.
The EPICURO trial tests MERIVAยฎ turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
Tavapadon, a once-daily oral medication, significantly improved motor function in early Parkinson's patients with fewer side effects.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
A completed Mount Sinai RCT tested whether HBOT can improve brain blood flow and cognition in diabetic elders with mild cognitive impairment.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
A Phase 4 real-world study comparing extended-release methylphenidate formulations for ADHD was terminated before yielding conclusions.
Nine-year study investigated whether solanezumab could slow memory decline in older adults with brain amyloid plaques.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
A Phase 4 RCT tests whether one bevacizumab injection matches two combined doses for neovascular AMD outcomes over 12 months.
New research reveals GLP-1 drugs like Ozempic significantly reduce depression, anxiety, and substance use disorders alongside weight management.
